ID

26789

Description

Letrozole, Anastrozole, Exemestane, or Tamoxifen Citrate in Treating Postmenopausal Women With Breast Cancer; ODM derived from: https://clinicaltrials.gov/show/NCT00893061

Link

https://clinicaltrials.gov/show/NCT00893061

Keywords

Versions (1)
  1. 10/24/17 10/24/17 -
Copyright Holder

See clinicaltrials.gov

Uploaded on

October 24, 2017

DOI

To request one please log in.

License

Creative Commons BY 4.0
Model comments :

You can comment on the data model here. Via the speech bubbles at the itemgroups and items you can add comments to those specificially.

Back to model comments
Itemgroup comments for :

Item comments for :

In order to download data models you must be logged in. Please log in or register for free.

Eligibility Breast Cancer NCT00893061

English

Eligibility Breast Cancer NCT00893061

1 forms  
Criteria
Description

Criteria

histologically confirmed breast cancer
Description

Breast Carcinoma

Data type

boolean

Alias
UMLS CUI [1]
C0678222
no metastatic disease
Description

Exclusion Neoplasm Metastasis

Data type

boolean

Alias
UMLS CUI [1,1]
C2828389
UMLS CUI [1,2]
C0027627
meets criteria for initiating adjuvant endocrine therapy
Description

Hormone Therapy Adjuvant

Data type

boolean

Alias
UMLS CUI [1,1]
C0279025
UMLS CUI [1,2]
C1522673
hormone receptor status:
Description

Hormone Receptor Status

Data type

boolean

Alias
UMLS CUI [1,1]
C0019929
UMLS CUI [1,2]
C0449438
estrogen receptor- and/or progesterone receptor-positive disease
Description

Disease Estrogen receptor positive | Disease Progesterone receptor positive

Data type

boolean

Alias
UMLS CUI [1,1]
C0012634
UMLS CUI [1,2]
C0279754
UMLS CUI [2,1]
C0012634
UMLS CUI [2,2]
C0279759
patient characteristics:
Description

Client Characteristics

Data type

boolean

Alias
UMLS CUI [1]
C0815172
postmenopausal, defined as no menstruation for ≥ 1 year, confirmed by a measurement of fsh and 17-beta-estradiol
Description

Postmenopausal state | Menstruation absent Duration FSH measurement | Menstruation absent Duration Estradiol Measurement

Data type

boolean

Alias
UMLS CUI [1]
C0232970
UMLS CUI [2,1]
C0497456
UMLS CUI [2,2]
C0449238
UMLS CUI [2,3]
C0202022
UMLS CUI [3,1]
C0497456
UMLS CUI [3,2]
C0449238
UMLS CUI [3,3]
C0014912
UMLS CUI [3,4]
C0242485
karnofsky performance status 80-100%
Description

Karnofsky Performance Status

Data type

boolean

Alias
UMLS CUI [1]
C0206065
native speaker of french
Description

Native speaker French language

Data type

boolean

Alias
UMLS CUI [1,1]
C0814951
UMLS CUI [1,2]
C0376246
beneficiary of a french social security insurance plan
Description

Insurance Beneficiary Social Security

Data type

boolean

Alias
UMLS CUI [1,1]
C3853043
UMLS CUI [1,2]
C0037435
no prior cognitive disorders
Description

Exclusion | Cognition Disorders

Data type

boolean

Alias
UMLS CUI [1]
C2828389
UMLS CUI [2]
C0009241
no depression or other confirmed active psychiatric disease
Description

Exclusion Criteria | Depressive disorder | Mental disorders

Data type

boolean

Alias
UMLS CUI [1]
C0680251
UMLS CUI [2]
C0011581
UMLS CUI [3]
C0004936
able to undergo the medical monitoring of the trial due to geographic, social or psychological reasons
Description

Monitoring Receive Ability

Data type

boolean

Alias
UMLS CUI [1,1]
C1516647
UMLS CUI [1,2]
C1514756
UMLS CUI [1,3]
C0085732
no personal or family history of thromboembolic disease
Description

Exclusion Criteria | Thromboembolism | Family history Thromboembolism

Data type

boolean

Alias
UMLS CUI [1]
C0680251
UMLS CUI [2]
C0040038
UMLS CUI [3,1]
C0241889
UMLS CUI [3,2]
C0040038
prior concurrent therapy:
Description

Therapeutic procedure

Data type

boolean

Alias
UMLS CUI [1]
C0087111
no prior adjuvant chemotherapy
Description

Exclusion Adjuvant Chemotherapy

Data type

boolean

Alias
UMLS CUI [1,1]
C2828389
UMLS CUI [1,2]
C0085533
no concurrent follow-up participation on another study
Description

Exclusion | Study Subject Participation Status | Clinical Study Follow-up

Data type

boolean

Alias
UMLS CUI [1]
C2828389
UMLS CUI [2]
C2348568
UMLS CUI [3]
C3274571
no concurrent treatment with psychotropic substances (i.e., long half life benzodiazepines, antipsychotics, anticholinesterase)
Description

Exclusion Criteria | Psychotropic Drugs | Benzodiazepines | Antipsychotic Agents | Cholinesterase Inhibitors

Data type

boolean

Alias
UMLS CUI [1]
C0680251
UMLS CUI [2]
C0033978
UMLS CUI [3]
C0005064
UMLS CUI [4]
C0040615
UMLS CUI [5]
C0008425
Back to the top of the page

Similar models

Eligibility Breast Cancer NCT00893061

1 forms
Name
Type
Description | Question | Decode (Coded Value)
Data type
Alias
Item Group
Breast Carcinoma
Item
histologically confirmed breast cancer
boolean
C0678222 (UMLS CUI [1])
Exclusion Neoplasm Metastasis
Item
no metastatic disease
boolean
C2828389 (UMLS CUI [1,1])
C0027627 (UMLS CUI [1,2])
Hormone Therapy Adjuvant
Item
meets criteria for initiating adjuvant endocrine therapy
boolean
C0279025 (UMLS CUI [1,1])
C1522673 (UMLS CUI [1,2])
Hormone Receptor Status
Item
hormone receptor status:
boolean
C0019929 (UMLS CUI [1,1])
C0449438 (UMLS CUI [1,2])
Disease Estrogen receptor positive | Disease Progesterone receptor positive
Item
estrogen receptor- and/or progesterone receptor-positive disease
boolean
C0012634 (UMLS CUI [1,1])
C0279754 (UMLS CUI [1,2])
C0012634 (UMLS CUI [2,1])
C0279759 (UMLS CUI [2,2])
Client Characteristics
Item
patient characteristics:
boolean
C0815172 (UMLS CUI [1])
Postmenopausal state | Menstruation absent Duration FSH measurement | Menstruation absent Duration Estradiol Measurement
Item
postmenopausal, defined as no menstruation for ≥ 1 year, confirmed by a measurement of fsh and 17-beta-estradiol
boolean
C0232970 (UMLS CUI [1])
C0497456 (UMLS CUI [2,1])
C0449238 (UMLS CUI [2,2])
C0202022 (UMLS CUI [2,3])
C0497456 (UMLS CUI [3,1])
C0449238 (UMLS CUI [3,2])
C0014912 (UMLS CUI [3,3])
C0242485 (UMLS CUI [3,4])
Karnofsky Performance Status
Item
karnofsky performance status 80-100%
boolean
C0206065 (UMLS CUI [1])
Native speaker French language
Item
native speaker of french
boolean
C0814951 (UMLS CUI [1,1])
C0376246 (UMLS CUI [1,2])
Insurance Beneficiary Social Security
Item
beneficiary of a french social security insurance plan
boolean
C3853043 (UMLS CUI [1,1])
C0037435 (UMLS CUI [1,2])
Exclusion | Cognition Disorders
Item
no prior cognitive disorders
boolean
C2828389 (UMLS CUI [1])
C0009241 (UMLS CUI [2])
Exclusion Criteria | Depressive disorder | Mental disorders
Item
no depression or other confirmed active psychiatric disease
boolean
C0680251 (UMLS CUI [1])
C0011581 (UMLS CUI [2])
C0004936 (UMLS CUI [3])
Monitoring Receive Ability
Item
able to undergo the medical monitoring of the trial due to geographic, social or psychological reasons
boolean
C1516647 (UMLS CUI [1,1])
C1514756 (UMLS CUI [1,2])
C0085732 (UMLS CUI [1,3])
Exclusion Criteria | Thromboembolism | Family history Thromboembolism
Item
no personal or family history of thromboembolic disease
boolean
C0680251 (UMLS CUI [1])
C0040038 (UMLS CUI [2])
C0241889 (UMLS CUI [3,1])
C0040038 (UMLS CUI [3,2])
Therapeutic procedure
Item
prior concurrent therapy:
boolean
C0087111 (UMLS CUI [1])
Exclusion Adjuvant Chemotherapy
Item
no prior adjuvant chemotherapy
boolean
C2828389 (UMLS CUI [1,1])
C0085533 (UMLS CUI [1,2])
Exclusion | Study Subject Participation Status | Clinical Study Follow-up
Item
no concurrent follow-up participation on another study
boolean
C2828389 (UMLS CUI [1])
C2348568 (UMLS CUI [2])
C3274571 (UMLS CUI [3])
Exclusion Criteria | Psychotropic Drugs | Benzodiazepines | Antipsychotic Agents | Cholinesterase Inhibitors
Item
no concurrent treatment with psychotropic substances (i.e., long half life benzodiazepines, antipsychotics, anticholinesterase)
boolean
C0680251 (UMLS CUI [1])
C0033978 (UMLS CUI [2])
C0005064 (UMLS CUI [3])
C0040615 (UMLS CUI [4])
C0008425 (UMLS CUI [5])
Back to the top of the page 

Contact

Please use this form for feedback, questions and suggestions for improvements.

Fields marked with * are required.

Help

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial